SIOG – International Society of Geriatric Oncology shared a post on LinkedIn:
“New in JGO
How well does chemoradiation for muscle-invasive bladder cancer perform outside the trial setting in older adults?
This SEER-Medicare analysis followed 283 patients aged 66–89 treated with chemoradiation for T2-T4a bladder cancer. At five years, progression-free survival was 47%, cancer-specific survival 53%, and overall survival 35%, lower than outcomes reported in prior clinical trials.
Female sex was linked to higher cancer-specific mortality, while higher education level was linked to lower mortality. The authors note the gap may reflect differences between trial and real-world populations, or variation in how completely chemoradiation is delivered in practice.”
Title: Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults
Authors: Piroz Bahar, Agustin Perez-Londono, Sumedh Kaul, Jason Efstathiou, Stephen B. Williams, Yong Shan, Peter Chang, Andrew Wagner, Aaron Fleishman, Aria Olumi, Boris Gershman
Read the Full Article on Journal of Geriatric Oncology
Other posts about SIOG on OncoDaily.